Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


Our top-notch dedicated system is used to design specialised libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q9NRX1

UPID:
PNO1_HUMAN

ALTERNATIVE NAMES:
Partner of NOB1

ALTERNATIVE UPACC:
Q9NRX1; A8K6Q0; Q53G13; Q8WVB8

BACKGROUND:
The RNA-binding protein PNO1, alternatively known as Partner of NOB1, is integral to the formation of the small eukaryotic ribosomal subunit. It associates with pre-rRNA in the nucleolus, aiding in RNA modifications and the targeted degradation of pre-ribosomal RNA. PNO1's regulation of rRNA dimethylation is vital for the maturation and function of ribosomes.

THERAPEUTIC SIGNIFICANCE:
Exploring the function of RNA-binding protein PNO1 offers a promising avenue for developing therapeutic interventions. As a key player in ribosomal assembly and RNA processing, targeting PNO1 could lead to innovative treatments for conditions associated with aberrant protein synthesis.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.